ACADIA PHARMACEUTICALS INC shared important news about its Alzheimer's drug trial results.

Sep 24, 2026, 5:15 PM ETTrialRead the original at sec.gov

Neutral

ACAD's Phase 2 topline mixed a narrowly missed main endpoint with a nominally significant secondary and a safety profile like placebo. The company will continue both Phase 3 trials, so the program stays active but approval chances are not clearly improved.

ACAD · ACADIA PHARMACEUTICALS INC

AI read · Neutral

The AI's read

The Phase 2 topline left ACAD with mixed evidence. The main efficacy measure narrowly missed the usual 0.05 cutoff (p=0.0603), while a key secondary was nominally significant and safety looked like placebo. Because the primary did not meet the cutoff but the safety and secondary signal support further testing, the company will continue both Phase 3 studies with protocol changes, leaving the clinical program active but the approval picture unchanged.

Get alerts for ACAD

Follow ACADIA PHARMACEUTICALS INC (ACAD) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for ACAD

Free on the App Store and Google Play, or on the web.